Answers are grounded in this paper and cite their sources.
Although currently approved to treat severe asthma and chronic spontaneous urticaria, omalizumab has also been an effective and safe add-on treatment for other allergic diseases. Namely, omalizumab has been proposed to be used as add-on therapy in patients with allergic rhinitis and asthma and undergoing specific allergen immunotherapy (AIT). AIT is the only treatment that modifies the natural history of IgE-mediated diseases. This brief review summarizes the available evidence and controversies on the efficacy and safety of omalizumab combined with specific AIT.
No takes yet. Share an insight, caveat, or question.
Filippo et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: